-+ 0.00%
-+ 0.00%
-+ 0.00%
Cereno Scientific Doses First Patient in Mid-stage Trial of CS1 Hypertension Drug
Share
Listen to the news
12:52 AM EST, 11/19/2026 (MT Newswires) -- Cereno Scientific (CRNO-B.ST) dosed the first patient in the phase 2b Epimode study of CS1, its lead drug candidate for pulmonary arterial hypertension, marking the start of randomized treatment. The trial will evaluate CS1's efficacy, safety, and tolerability in a larger, randomized, placebo-controlled setting to determine whether the positive efficacy signals from the earlier phase 2a study can be replicated, the Swedish biotechnology company said Wednesday. Topline results are targeted for the fourth quarter of 2028, with patient recruitment expected to be completed in 2027, subject to progress and funding.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending